ArticleThe AAPS journal2023
Robust and Adaptive Two-stage Designs in Nonlinear Mixed Effect Models.
Article in The AAPS journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Advances and Further Comparison of Software Tools for Fisher Information Matrix-Based Design Evaluation in Pharmacometrics.Pharmaceutical research · 2026Article
- Design, optimization, and inference of biphasic decay of infectious virus particles.Journal of theoretical biology · 2025Article
- Design, optimization, and inference of biphasic decay of infectious virus particles.bioRxiv : the preprint server for biology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To get informative studies for nonlinear mixed effect models (NLMEM), design optimization can be performed based on Fisher Information Matrix (FIM) using the D-criterion. Its computation requires knowledge about models and parameters, which are often prior guesses. Thus, adaptive designs composed of several stages may be used. Robust approach can also be used to account for various candidate models. In the estimation step of a given stage, model selection (MS) or model averaging (MA) can be performed. In this work we propose a new two-stage adaptive design strategy, based on the robust expected FIM and MA over several candidate models. The methodology is applied to a clinical trial simulation in ophthalmology to optimize doses and time measurements. A set of dose-response candidate models is defined, and one-stage designs are compared to two-stage 50/50 designs (i.e., each stage performed with half of the available subjects), using either local optimal design or robust design, and performing analysis with one model, MS or MA. Performing a two-stage design with MS at the interim analysis can correct the choice of a wrong model for designing the first stage. Overall, starting from a robust design (1- or 2-stage) is valuable and leads to reasonable bias and precision. The proposed robust adaptive design strategy is a new tool to design longitudinal studies that could be used in different therapeutic areas.
Indexed as
Identifiers
37466809What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.